Pathway to Cures Announces Venture Investment in Five Liters

Pathway to Cures (P2C) announced ts investment in Five Liters, a subsidiary of Spark Biomedical, to develop therapies for treating inheritable blood and bleeding disorders. Pathway to Cures, an affiliate of the National Bleeding Disorders Foundation, is a venture philanthropy fund focused on early-stage companies developing cures, therapies, or enabling technologies in support of the inheritable blood and bleeding disorders community.

Investing in Five Liters’ early-stage research is a critical step in addressing unmet needs of patients living with inheritable blood and bleeding disorders through innovative non-invasive, non-pharmacological treatments” said Michael Recht, MD, PhD, MBA. Dr. Recht is Chief Medical and Scientific Officer at both Pathway to Cures and the National Bleeding Disorders Foundation (NBDF) and chairs the Pathway to Cures Scientific Advisory Group.